Trichlortriethylamine (TS-160 Spofa) in combination chemotherapy of malignant lymphomas.
Thirteen patients with disseminated malignant lymphomas were treated with combination chemotherapy which included trichlortriethyl amine (TS-160), vincristine (Oncovin), procarbazine hydrochloride (Natulan) and prednisone. All patients but two received some form of chemotherapy and/or radiotherapy prior to being started on four-drug regimen. Good response to the combination chemotherapy was recorded in 84% of patients, while complete remission was achieved in 23% of cases. Drug toxicity has not proved to be a major problem in the combination used. Nausea and vomiting were the side effects the most frequently observed.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D011344:Procarbazine; C009802:2,2',2''-trichlorotriethylamine; D014750:Vincristine; D011241:Prednisone